Triple therapy takes on rare, aggressive kidney cancer
NCT ID NCT07715565
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of two immunotherapies (ipilimumab and sintilimab) plus a targeted drug (lenvatinib) as a first treatment for people with a rare and aggressive form of kidney cancer called TFE3-rearranged renal cell carcinoma. The study enrolls about 66 participants who have not received prior systemic therapy. The main goal is to see how many patients' tumors shrink or disappear, while also tracking side effects and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of three drugs: ipilimumab (an immunotherapy that boosts immune attack on cancer), sintilimab (another immunotherapy that releases the brakes on immune cells), and lenvatinib (a targeted therapy that blocks blood vessel growth to tumors)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for people with this rare, aggressive kidney cancer, potentially shrinking tumors and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial (66 people) with no control group, so results may not prove the combination is better than existing options. The three-drug regimen also carries a higher risk of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Chengdu, Sichuan 610000
Chengdu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Nerve block may slash opioid use after kidney surgery
- Immunotherapy combo may boost rectal cancer treatment
- New cocktail aims to make immunotherapy work for common colorectal cancer
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors